Evidence map›Paper›PMID 24666357›Full record

ArticleClinical and experimental immunology2014

Serum autoantibodies directed against transglutaminase-2 have a low avidity compared with alloantibodies against gliadin in coeliac disease.

K A Gelderman, A C A D Drop, L A Trouw, H J Bontkes, G Bouma, I M W van Hoogstraten, B M E von Blomberg

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Clinical and experimental immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Avidity of anti-phospholipid antibodies in relation to their levels.Central-European journal of immunology · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

K A GeldermanDepartment of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
A C A D Drop
L A Trouw
H J Bontkes
G Bouma
I M W van Hoogstraten
B M E von Blomberg
Amsterdam UMC Location Vrije Universiteit Amsterdam · NLLeiden University Medical Center · NLSanquin · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coeliac disease is characterized by intolerance to gliadin and related gluten components present in wheat, barley and rye. Coeliac disease patients harbour antibodies directed against alloantigens such as gliadin, but also against the autoantigen transglutaminase-2 (TG2). The type and quality of antibody responses provides insight into the underlying immune activation processes. Therefore, in this study we have analysed the avidity of the antibody response directed against the autoantigen TG2 and compared this with antibody responses against the alloantigens gliadin and Escherichia coli. We observed that the immunoglobulin (Ig)A autoantibody response directed against TG2 is of low avidity compared with the IgA response against the alloantigens gliadin and E. coli in the same patients; the same was true for IgG, both in IgA-deficient and in -sufficient coeliac patients. The observed avidities appear not to be related to disease stage, antibody levels, age or duration of exposure to gluten. In conclusion, in coeliac disease there is a clear difference in avidity of the antibody responses directed against the auto- and alloantigens, indicating different regulation or site of initiation of these responses.

Indexed as

Antibody AffinityAdolescentAdultAgedAged, 80 and overAntibodies, BacterialAutoantibodiesCeliac DiseaseChildChild, PreschoolEscherichia coliGliadinGlutensGTP-Binding ProteinsHordeumHumansAntibodies, BacterialAutoantibodiesGliadinGlutensGTP-Binding ProteinsImmunoglobulin AImmunoglobulin GIsoantibodiesProtein Glutamine gamma Glutamyltransferase 2Transglutaminasesantibodiesaviditycoeliac diseasegliadintransglutaminase

Identifiers

PMID24666357
PMCPMC4089157
OpenAlexW1533872119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.